Annabel Samimy
Stock Analyst at Stifel
(4.45)
# 306
Out of 5,123 analysts
56
Total ratings
49.06%
Success rate
35.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Buy | $20 → $17 | $4.41 | +285.49% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $10.94 | +64.53% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $49.37 | +11.40% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $10.26 | +338.60% | 3 | Dec 19, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $35 → $40 | $27.49 | +45.51% | 2 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $28.21 | +84.33% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $36.05 | +38.70% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $22.56 | +112.77% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $191.69 | +19.99% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $73.21 | +22.93% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $76.43 | +89.72% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.92 | +265.85% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.80 | +193.10% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.02 | +124.44% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $12.41 | +93.39% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $26.29 | +204.30% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $163.15 | +40.97% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.10 | +2,081.82% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.19 | +34,146.58% | 3 | Apr 16, 2020 |
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $4.41
Upside: +285.49%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $10.94
Upside: +64.53%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $49.37
Upside: +11.40%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $10.26
Upside: +338.60%
Oculis Holding AG
Dec 19, 2025
Maintains: Buy
Price Target: $35 → $40
Current: $27.49
Upside: +45.51%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $28.21
Upside: +84.33%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $36.05
Upside: +38.70%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $22.56
Upside: +112.77%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $191.69
Upside: +19.99%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $73.21
Upside: +22.93%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $76.43
Upside: +89.72%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $4.92
Upside: +265.85%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.80
Upside: +193.10%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.02
Upside: +124.44%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $12.41
Upside: +93.39%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $26.29
Upside: +204.30%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $163.15
Upside: +40.97%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.10
Upside: +2,081.82%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.19
Upside: +34,146.58%